anthrax vaccine + plague vaccine

The **anthrax vaccine + plague vaccine** (specifically the recombinant candidate **rVAP**) is a bivalent investigational vaccine designed to provide simultaneous protection against *Bacillus anthracis* and *Yersinia pestis*. Developed primarily for biodefense applications, the vaccine utilizes recombinant protein technology to deliver the Protective Antigen (PA) of *B. anthracis* and a fusion protein consisting of the F1 and V antigens of *Y. pestis*. The mechanism of action involves the induction of a robust humoral immune response, generating neutralizing antibodies that prevent the entry of anthrax toxins into host cells and facilitate the immune clearance of the plague bacterium. This combination approach aims to simplify immunization schedules for military personnel and first responders while providing a more refined and less reactogenic alternative to older, licensed whole-cell or filtrate-based vaccines.

Other names

recombinant anthrax and plague vaccinerecombinant bivalent anthrax and plague vaccine